Online first
Clinical vignette
Published online: 2024-11-26

open access

Page views 37
Article views/downloads 20
Get Citation

Connect on Social Media

Connect on Social Media

Complications associated with accelerated 5-fluorouracil (5-Fu) infusion

Małgorzata B. Radom1, Aneta L. Zygulska2, Piotr J. Wysocki3

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Seifert P, Baker L, Reed M, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975; 36(1): 123–128, doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c.
  2. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park). 1998; 12(10 Suppl 7): 19–22.
  3. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol. 2003; 8(3): 132–138.
  4. van Ku, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5‐fluorouracil‐associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000; 6(12): 4705–4712.
  5. Piedbois P, Rougier P, Buyse M, et al. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16(1): 301–308.